Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Oric Pharmaceuticals (ORIC) EBITDA (2019 - 2026)

Oric Pharmaceuticals filings provide 8 years of EBITDA readings, the most recent being -$36.8 million for Q1 2026.

  • Quarterly EBITDA fell 22.03% to -$36.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$135.7 million through Mar 2026, down 2.44% year-over-year, with the annual reading at -$129.1 million for FY2025, 1.05% down from the prior year.
  • EBITDA hit -$36.8 million in Q1 2026 for Oric Pharmaceuticals, down from -$30.3 million in the prior quarter.
  • Across five years, EBITDA topped out at -$20.4 million in Q4 2022 and bottomed at -$36.8 million in Q1 2026.
  • Average EBITDA over 5 years is -$28.4 million, with a median of -$27.7 million recorded in 2023.
  • The largest annual shift saw EBITDA plummeted 44.94% in 2022 before it rose 17.23% in 2025.
  • Oric Pharmaceuticals' EBITDA stood at -$20.4 million in 2022, then plummeted by 35.86% to -$27.7 million in 2023, then tumbled by 32.3% to -$36.6 million in 2024, then rose by 17.23% to -$30.3 million in 2025, then decreased by 21.46% to -$36.8 million in 2026.
  • Per Business Quant, the three most recent readings for ORIC's EBITDA are -$36.8 million (Q1 2026), -$30.3 million (Q4 2025), and -$32.2 million (Q3 2025).